Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Core Insights - The U.S. FDA has accepted Boundless Bio's Investigational New Drug (IND) application for BBI-940, a novel Kinesin oral degrader program, enabling the initiation of a first-in-human clinical trial for metastatic breast cancer in the first half of 2026 [1][2][3] - The company has decided to discontinue the POTENTIATE trial for BBI-355 and BBI-825, focusing resources on programs with the highest potential for clinical impact [4] - The revised operating plan extends the company's operational runway into the second half of 2028, aligning with the anticipated initial clinical proof-of-concept readout for BBI-940 [5] Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA), which is linked to oncogene amplification in 14% to 17% of cancer patients [6] - The company is developing BBI-940 as a potentially first-in-class orally bioavailable Kinesin degrader aimed at treating oncogene amplified tumors [6] Clinical Development - BBI-940 has shown potent anti-tumor activity in various cancer cell lines and mouse xenograft models, indicating its potential effectiveness as a treatment [2] - The KOMODO-1 trial will be the first clinical trial for BBI-940, expected to provide initial proof-of-concept data within the company's cash runway timeline [2][3]